The role of high-dose therapy and autologous stem-cell transplantation (ASCT) in the treatment of multiple myeloma (MM) has continued to evolve in recent years. The novel agents thalidomide, bortezomib, and lenalidomide have been successfully incorporated into induction therapy in preparation for ASCT and are currently being investigated also as post-ASCT consolidation and maintenance therapy. Consolidation treatment is generally short term and aims to increase the frequency and depth of response obtained with the previous treatment phases, including novel agent-based induction therapy and ASCT. This review will focus on recent trials of novel agents as post-ASCT consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the ASCT sequence for MM patients.
Role of consolidation therapy in transplant eligible multiple myeloma patients / Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E.. - In: SEMINARS IN ONCOLOGY. - ISSN 0093-7754. - STAMPA. - 40:(2013), pp. 610-617. [10.1053/j.seminoncol.2013.07.001]
Role of consolidation therapy in transplant eligible multiple myeloma patients.
CAVO, MICHELE;BRIOLI, ANNAMARIA;TACCHETTI, PAOLA;MANCUSO, KATIA;ZAMAGNI, ELENA
2013
Abstract
The role of high-dose therapy and autologous stem-cell transplantation (ASCT) in the treatment of multiple myeloma (MM) has continued to evolve in recent years. The novel agents thalidomide, bortezomib, and lenalidomide have been successfully incorporated into induction therapy in preparation for ASCT and are currently being investigated also as post-ASCT consolidation and maintenance therapy. Consolidation treatment is generally short term and aims to increase the frequency and depth of response obtained with the previous treatment phases, including novel agent-based induction therapy and ASCT. This review will focus on recent trials of novel agents as post-ASCT consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the ASCT sequence for MM patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
